



NZX/ASX/Media release

1 September 2016

EC antitrust approval received. Implementation of the Scheme expected to occur on 13 September 2016

Nuplex Industries Limited (Nuplex, NZX/ASX code: NPX) announces that it has received confirmation from Allnex Belgium SA/NV (**Allnex**) that the combination of the Allnex and Nuplex businesses received antitrust clearance from the European Commission (“EC”).

Having received this approval, implementation of the Scheme is now expected to occur on 13 September 2016.

Nuplex shares will cease trading on the NZX and ASX at close of trade on Monday 5 September 2016.

Shareholders who hold shares on the Record Date (7.00pm on Wednesday 7 September 2016) will receive the Scheme Consideration of NZ\$5.43 per share.

Due to the delay in implementation of the Scheme, solely as a result of the delay in receiving EC antitrust clearance, a compensatory dividend payment of 3.150 NZ cents per share is expected to be payable to Nuplex shareholders who hold Nuplex shares on the Record Date, being 7.00pm on Wednesday 7 September 2016.

The proposed timetable for implementation of the Scheme and payment of the compensatory dividend is:

| | |
|---|--|
| Thursday 1 September 2016 | Receipt of EC antitrust approval |
| Close of trading on each of NZX and ASX - Monday 5 September 2016 | Trading in NPX shares on NZX and ASX ceases |
| 7.00pm (NZ time) – Wednesday 7 September 2016 | Scheme and Dividend Record Date |
| Monday 12 September 2016 | Dividend payment date |
| Tuesday 13 September 2016 | Scheme Implementation Date – Scheme Consideration payment date |
| Close of trading on each of NZX and ASX – Tuesday 13 September 2016 | Nuplex delists from the NZX Main Board and ASX |

The Scheme is binding on all Nuplex shareholders, subject to satisfaction or waiver of the remaining conditions to the Scheme (described below). If you hold Nuplex shares on the Record Date, being 7.00pm (NZ time) Wednesday 7 September 2016:

- you will be paid the compensatory dividend on Monday 12 September 2016;
- you will be paid the Scheme Consideration on Tuesday 13 September 2016; and
- your Nuplex shares will be transferred to Allnex on Tuesday 13 September 2016.

If you wish to participate in the Scheme, you do not need to do anything further. If you do not wish to participate in the Scheme, you must sell your Nuplex shares prior to close of trading on the NZX or ASX on Monday 5 September 2016. After this date, trading in Nuplex shares will cease.

As Allnex will acquire all of the shares of Nuplex as a result of the Scheme, Nuplex intends to delist from the NZX Main Board and ASX with effect from close of trading on the NZX and ASX on the Scheme Implementation Date.

All relevant regulatory approvals to the Scheme have now been obtained.

Nuplex expects that the remaining conditions relating to certain specified events or circumstances not occurring before 8.00 (NZ time) on the Implementation Date (as described in section 13.2 of the Scheme Booklet) will be satisfied. These include no Material Adverse Change, no Nuplex Prescribed Occurrence and no breach of certain undertakings and warranties given by Nuplex to Allnex.

Ends

For more information regarding Nuplex

| Investors | New Zealand media | Australian media |
|--|---|---|
| Josie Ashton, Nuplex +612 8036 0906 josie.ashton@nuplex.com | Louisa Jones, Porter Novelli +64 21 299 2628 louisaj@porternovelli.kiwi | Paula Hannaford, Kreab +61 2 9552 8936 phannaford@kreab.com |

For more information regarding Allnex

| Company enquiries | New Zealand media | Australian media |
|--|--|--|
| Stéphanie Heng, Allnex +32 2 560 4630 stephanie.heng@allnex.com | Jane Sweeney, Anthem +64 21 910 008 jane@anthem.co.nz | Ashley Rambukwella, FCR +61 407 231 282 a.rambukwella@fcr.com.au |

About Nuplex

Nuplex is a leading, global manufacturer of resins used in paints, coatings and structural materials with annual sales of c.NZ\$1.5 billion (c.US\$1 billion). Listed on the NZX and the ASX, Nuplex is a global leader in rheology control coatings technology, as well as performance and industrial coating resins, particularly for Automotive OEM, Vehicle Re-finish, Wood, and Protective coatings. From its 16 production sites located across Asia, Europe, America and Australia and New Zealand, Nuplex has customers in over 80 countries worldwide. Through its global R&D network of local technical service support, regional R&D centers and a dedicated Innovation Centre in The Netherlands, Nuplex works in partnership with its customers to develop the right solution for their coatings challenges.

About Allnex

Allnex, formerly Cytec Industries' Coating Resins business and acquired by Advent in 2013, with sales of approximately US\$1.5 billion, is a leading global producer of coating resins and additives for architectural, industrial, protective, automotive and special purpose coatings and inks. Allnex is recognized as a specialty chemicals pioneer and offers an extensive range of

products including innovative liquid resins & additives, radiation cured and powder coating resins & additives and cross linkers for use on wood, metal, plastic, and other surfaces. Today, Allnex has a strong global presence with 17 manufacturing sites and 12 research & technology support facilities throughout the world, focusing on assisting its approximately 3,000 customers to rapidly bring advanced coating solutions to market.

About Advent International

Founded in 1984, Advent International is one of the largest and most experienced global private equity firms and a leading investor in the global Chemicals industry. Advent's investment philosophy is centred on supporting leading management teams and providing resources for further growth in order to execute on a mutually developed strategy and investment case. To date, Advent has raised cumulative capital of US\$53 billion and has executed over 310 transactions including over 30 investments in the Chemicals industry. Advent has a strong track record of making significant and successful investments, with recent chemicals transactions including Allnex (formerly Cytec Industries' Coating Resins business), Oxea, Maxam, Viakem and Grupo Transmerquim. Advent also has extensive experience in conducting Public-to-Private transactions, with recent examples including Douglas, Mediq and Unit 4.